Sign in
CompletedNo phase

Monitoring Mitophagy In Myeloid Cells Upon Intensive Care

Key facts

Who runs it
Centre Hospitalier Universitaire Dijon
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
205 people enrolled
Started
25 Aug 2021
Ended
13 Mar 2025
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Blood sampling at inclusion
  • Blood sampling at 24 hours
  • Data collection
Record updated
24 June 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Criteria common to all 4 groups:
  • Patient (and/or trusted person/health care proxy or relative) or volunteer who provided oral consent after receiving information about the study, or patient included in emergency situation
  • Age ≥ 18 years; Common criteria for patients
  • Admission to the Intensive Care Unit or the Anesthesia and Intensive Care Unit of the Dijon University Hospital

Who cannot take part

  • Patients hospitalized within 3 months prior to inclusion for sepsis
  • Patients receiving therapy known to modulate mitochondrial function, mitochondrial biogenesis or mitophagy (chloroquine, hydroxychloroquine, rapamycin, carbamazepine, resveratrol, sildenafil)
  • Known primary or secondary immune deficiency (radiotherapy, chemotherapy, immunosuppressive treatment or systemic corticosteroid therapy in the 3 months preceding inclusion (> 0.15 mg/kg/d of prednisone equivalent for more than 2 weeks or "bolus" greater than 2mg/kg/d of prednisone equivalent), HIV infection, primary cellular immune deficiency)
  • Patients with COVID-19
  • Person not affiliated to national health insurance
  • Person subject to a measure of legal protection (curatorship, guardianship)
  • Person subject to limited judicial protection
  • Pregnancy or breastfeeding

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Severe infections (sepsis) are a frequent cause of admission to the intensive care unit. Sepsis represent a significant risk for the health of patients in the short and medium term. Sepsis are notably linked to a change in the function of immune cells. In some patients, a state of pseudo-dormancy of monocyte and macrophage immune cells, called myeloid cell immunosuppression, is observed. This situation, which leads to a worsening of the infection, must be avoided because it represents a danger for the patient, even during antibiotic therapy. At present, these events are still very poorly understood. Research is needed to understand how the immunosuppression of myeloid cells occurs in order to adapt existing treatments or to find new ones.

Read full original descriptionShow less

Laboratory work on animal models of sepsis has shown that this state of myeloid cell immunosuppression is closely linked to a modification of energy production by myeloid cells (monocytes and macrophages). The function of the mitochondria ("energy factory" of the cells) in these cells is impaired. Thus, restoring mitochondrial function in myeloid cells could be a therapeutic solution against the immunosuppression of myeloid cells during severe sepsis.

The aim of this study is to verify whether alterations in mitochondrial function in myeloid cells occur in both patients with and without bacterial infection.

The 4 groups in the trial

  • Patients without sepsisExisting treatment, for comparison

    patient without sepsis admitted to the Intensive Care Unit or the Anesthesia and Intensive Care Unit of the Dijon University Hospital

    Treatment: Blood sampling at inclusion, Blood sampling at 24 hours, and Data collection

  • Patients with sepsisTreatment being tested

    Patients with sepsis admitted to the Intensive Care Unit or the Anesthesia and Intensive Care Unit of the Dijon University Hospital

    Treatment: Blood sampling at inclusion, Blood sampling at 24 hours, and Data collection

  • Patients with septic shockTreatment being tested

    Patients with septic shock admitted to the Intensive Care Unit or the Anesthesia and Intensive Care Unit of the Dijon University Hospital

    Treatment: Blood sampling at inclusion, Blood sampling at 24 hours, and Data collection

  • Healthy volunteersExisting treatment, for comparison

    Treatment: Blood sampling at inclusion and Data collection

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
24 June 2025